Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial

Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs). Tuberculosis remains the leading cause of HIV-related morbidity and mortality in LMICs. Rifampicin is a key agent i...

Descripción completa

Detalles Bibliográficos
Autores principales: Griesel, Rulan, Hill, Andrew, Meintjes, Graeme, Maartens, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063551/
https://www.ncbi.nlm.nih.gov/pubmed/33954265
http://dx.doi.org/10.12688/wellcomeopenres.16473.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063551/
https://www.ncbi.nlm.nih.gov/pubmed/33954265
http://dx.doi.org/10.12688/wellcomeopenres.16473.1

Ejemplares similares